Leading the way to safer medication
 Crosscheck  Recommender

Bimatoprost

Brand names: BIMATIM-VISION (in combination) BIMATO-VISION BIRMOST CAREPROST DURYSTA GANFORT (in combination) GLAROST LATISSE LUMIGAN VISTITAN VIZIMACO (in combination)

Interactions

Active ingredient Bimatoprost interacts in the following cases:

Prostaglandin analogues

There is a potential for the IOP-lowering effect of prostaglandin analogues to be reduced in patients with glaucoma or ocular hypertension when used with other prostaglandin analogues.

Effects on ability to drive and use machines

Bimatoprost has negligible influence on the ability to drive and use machines. As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.

Lactation

It is unknown whether bimatoprost is excreted in human breast milk. Animal studies have shown excretion of bimatoprost in breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue from bimatoprost therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Pregnancy

There are no adequate data from the use of bimatoprost in pregnant women. Animal studies have shown reproductive toxicity at high maternotoxic doses. Bimatoprost should not be used during pregnancy unless clearly necessary.

Hair growth

There is a potential for hair growth to occur in areas where bimatoprost solution comes repeatedly in contact with the skin surface. Thus, it is important to apply bimatoprost as instructed and avoid it running onto the cheek or other skin areas.

Cystoid macular oedema

Cystoid macular oedema has been uncommonly reported (≥1/1,000 to <1/100) following treatment with bimatoprost 0.3 mg/ml eye drops, solution. Therefore, bimatoprost should be used with caution in patients with known risk factors for macular oedema (e.g. aphakic patients, pseudophakic patients with a torn posterior lens capsule).

Asthma, COPD

Bimatoprost has not been studied in patients with compromised respiratory function. While there is limited information available on patients with a history of asthma or COPD, there have been reports of exacerbation of asthma, dyspnoea and COPD, as well as reports of asthma, in post marketing experience. The frequency of these symptoms is not known. Patients with COPD, asthma or compromised respiratory function due to other conditions should be treated with caution.

Pregnancy

There are no adequate data from the use of bimatoprost in pregnant women. Animal studies have shown reproductive toxicity at high maternotoxic doses. Bimatoprost should not be used during pregnancy unless clearly necessary.

Nursing Mothers

It is unknown whether bimatoprost is excreted in human breast milk. Animal studies have shown excretion of bimatoprost in breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue from bimatoprost therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Carcinogenesis, Mutagenesis and Fertility

Fertility

There are no data on the effects of bimatoprost on human fertility.

Effects on Ability to Drive and Use Machines

Bimatoprost has negligible influence on the ability to drive and use machines. As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines.